Accelerate Drug Development with Strategic Partnerships: Maximizing Integrated Partnership Performance to Accelerate Drug Development and Increase Valuation
From Duplicate to Singlicate: Advancing PD Immunoassays for Clinical Efficiency
Join us for a practical case study on converting a pharmacodynamic bridging immunoassay for target shedding of a monoclonal antibody from duplicate to singlicate format. Built on an ECL platform and validated to ICH M10 standards, this session explores how the transition was made without sacrificing data quality across Phase I and II clinical studies.
Clinical programs are under growing pressure to do more with less sample, less time and fewer resources. Singlicate immunoassay formats offer a compelling path forward, but making the switch requires solid scientific justification and rigorous validation. This session takes you through a real-world conversion of a PD bridging immunoassay on an ECL platform, showing step by step how that transition was planned, executed, and confirmed as fit-for-purpose for Phase I and II clinical studies.
We will cover everything from reconfiguring standards and QCs to navigating ICH M10 validation requirements, grounded in actual performance data and cross-lab concordance results. Whether you are actively considering singlicate formats or simply want to understand the science behind the decision, this is a session worth your time.
What You'll Walk Away With
- A clear framework for scientifically justifying the duplicate-to-singlicate conversion in a regulated setting
- Practical ICH M10 validation strategies: what to test, why it matters, and how to read the results with confidence
- Real performance data covering bias, variability and cross-lab concordance from a live clinical program
- Risk mitigation approaches you can tailor to your own assay format and study requirements
Speaker
Aparna Kasinath
Aparna Kasinath brings over 23 years of experience in bioanalytical sciences, with expertise in immunoassay development, validation, and PK/immunogenicity studies for biologics, biosimilars, and vaccines. She currently leads Syngene’s large and small molecule bioanalytical laboratories and oversees GLP compliance. Aparna is a recognized contributor to global scientific forums and has co-authored multiple AAPS Journal recommendations on immunogenicity and neutralizing antibody assays. She played a key role in establishing one of India’s earliest COVID-19 RT-PCR testing labs and contributed to serology assay validation. She holds a PhD from Sardar Patel University and is a recipient of the ‘Syngenite of the Year’ award.
Moderator
Pallavi Karnik
Dr. Pallavi V. Karnik brings over 25 years of experience across drug discovery, biologics, biosimilars, and cell & gene therapy. She has deep expertise in analytical development, assay design, and product characterization for modalities including monoclonal antibodies, ADCs, peptides, and gene therapy products. Pallavi has led large teams and supported multiple programs through development and global regulatory submissions, including interactions with agencies such as the US FDA. Her strengths span CMC strategy, regulatory compliance, and end-to-end product development aligned with global standards. She has contributed to several publications and patents and holds a PhD in life sciences.